Gilead strikes deal to make remdesivir coronavirus treatment in 127 countries

The company behind the experimental coronavirus treatment remdesivir has signed non-exclusive licensing deals with five drugmakers based in India and Pakistan to make and sell the antiviral medicine in 127 countries.

Gilead Sciences said the agreements cover almost all of the world’s low-income and lower-middle income countries, including Afghanistan, India, North Korea, Pakistan and South Africa.

The pacts also include several upper-middle and high-income nations.

This month both the US and Japan authorised remdesivir as a treatment for Covid-19 patients.

Many other pharmaceutical companies are racing to develop a Covid-19 drug or vaccine to combat the pandemic.

You might also like

411

Central University of Punjab honours Kenyan police officer with highest award

Crime & Scandal

3 men sentenced to death for 1981 caste massacre

411

More than 100 passengers rescued from Pakistan train attack